Letter: ustekinumab for the treatment of post‐surgical and refractory Crohn's disease
Alimentary Pharmacology & Therapeutics2021Vol. 53(7), pp. 859–860
Citations Over TimeTop 18% of 2021 papers
Abstract
LINKED CONTENT This article is linked to Biemans et al paper. To view this article, visit https://doi.org/10.1111/apt.15745
Related Papers
- Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease(2014)
- → Ustekinumab: a novel therapeutic option in Crohn’s disease(2016)10 cited
- → 985 EFFICACY OF MIRIKIZUMAB IN COMPARISON TO USTEKINUMAB IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3 VIVID 1 STUDY(2024)2 cited
- → EP1276: USTEKINUMAB HAS COMPARABLE LONG-TERM EFFECTIVENESS AS ANTI-TNF AGENTS IN BIOLOGIC-NAÏVE PATIENTS WITH CROHN'S DISEASE(2022)
- → Su1713 IMPACT OF IMMEDIATE OPTIMIZATION OF USTEKINUMAB ON MEDIUM TERM TARGETS IN SEVERE CROHN'S DISEASE: THE MUST STUDY(2023)